Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have patented C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
